Drug intelligence / Profile preview

MGC030

Development stage: Preclinical
Lead developer: MacroGenics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MGC030 is a preclinical antibody-drug conjugate (ADC) developed by MacroGenics. It utilizes a topoisomerase 1 inhibitor (TOP1i) as its cytotoxic payload and targets an undisclosed antigen that is expressed across several solid tumors. The specific target antigen has not been publicly disclosed, and there are currently no approved therapeutics directed at this target. An Investigational New Drug (IND) application for MGC030 is planned for 2026[2][3][7][10].

Beyond the preview

Go deeper on MGC030.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MGC030.

Explore the full profile